{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:42:59Z","timestamp":1782351779590,"version":"3.54.5"},"reference-count":29,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victor Babes University of Medicine and Pharmacy Timisoara"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Multiple sclerosis (MS) is a chronic, progressive neurological disorder that significantly impacts quality of life and functionality. Ocrelizumab, a monoclonal antibody targeting CD20-positive B cells, has emerged as a treatment for relapsing-remitting MS (RRMS). This study aimed to assess the impact of ocrelizumab on disease progression and quality of life over a longitudinal course, utilizing clinical criteria and magnetic resonance imaging (MRI) analyses. Conducted at the Neurology Department of Pius Brinzeu Clinical Emergency Hospital in Western Romania from 2020 to 2023, this observational study enrolled 93 patients with RRMS who commenced ocrelizumab therapy. The study employed the Expanded Disability Status Scale (EDSS) and MRI to evaluate disease progression, while quality of life was assessed using the World Health Organisation Quality of Life (WHOQOL) questionnaire, Beck Depression Index (BDI), and MOCA scales. Significant improvements were observed post-treatment. EDSS scores decreased from 4.61 to 4.08 (p = 0.038), indicating reduced disability. MRI analyses showed a substantial decrease in expansive lesions (from 67.74% to 26.88%, p &lt; 0.001) and an increase in stationary lesions (from 32.26% to 73.12%, p &lt; 0.001). Quality of life improvements were notable in the physical (from 58.42 to 64.84, p = 0.005) and environmental domains (from 63.21 to 68.44, p = 0.033). Cognitive functions, assessed via Montreal Cognitive Assessment (MOCA), showed a significant total score increase from 20.38 to 22.30 (p &lt; 0.001). Subgroup analysis revealed more pronounced effects in females and younger patients, with a significant reduction in depressive symptoms measured by BDI scores (from 14.35 to 11.62, p = 0.003). Ocrelizumab significantly reduced disease activity and disability in RRMS patients, as demonstrated by improvements in EDSS scores and MRI findings. Quality of life and cognitive functions also showed considerable enhancements. These findings support ocrelizumab\u2019s efficacy in not only managing MS symptoms but also improving overall patient well-being.<\/jats:p>","DOI":"10.3390\/diseases12060127","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T04:48:12Z","timestamp":1718599692000},"page":"127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis"],"prefix":"10.3390","volume":"12","author":[{"given":"Amanda Claudia","family":"Schuldesz","sequence":"first","affiliation":[{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1709-1243","authenticated-orcid":false,"given":"Ram Kiram","family":"Maganti","sequence":"additional","affiliation":[{"name":"School of General Medicine, Sri Devaraj Urs Academy of Higher Education and Research, Kolar 563101, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1971-6901","authenticated-orcid":false,"given":"Raluca","family":"Tudor","sequence":"additional","affiliation":[{"name":"Discipline of Neurology, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7293-3414","authenticated-orcid":false,"given":"Amalia","family":"Cornea","sequence":"additional","affiliation":[{"name":"Discipline of Neurology, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Prodan","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Olivia","family":"Toma","sequence":"additional","affiliation":[{"name":"Discipline of Dermatology, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"},{"name":"Department of Dermatology, Timisoara Municipal Emergency Hospital, 300254 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0776-0809","authenticated-orcid":false,"given":"Roxana Manuela","family":"Fericean","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Timisoara Municipal Emergency Hospital, 300254 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Simu","sequence":"additional","affiliation":[{"name":"Discipline of Neurology, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1007\/s00415-020-10107-y","article-title":"A global view of comorbidity in multiple sclerosis: A systematic review with a focus on regional differences, methodology, and clinical implications","volume":"268","author":"Hauer","year":"2021","journal-title":"J. Neurol."},{"key":"ref_2","first-page":"e24294","article-title":"Multiple Sclerosis and Autoimmunity: A Veiled Relationship","volume":"14","author":"Barkhane","year":"2022","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lee, C.-Y., and Chan, K.-H. (2024). Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010120"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"824926","DOI":"10.3389\/fneur.2022.824926","article-title":"Therapeutic Advances in Multiple Sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_5","first-page":"CD013247","article-title":"Ocrelizumab for multiple sclerosis","volume":"5","author":"Lin","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"McCool","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/21556660.2021.1989193","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in an Arab population","volume":"10","author":"Ouanes","year":"2021","journal-title":"J. Drug Assess."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/acn3.51282","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population","volume":"8","author":"Diaz","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: Time for early treatment with high-efficacy drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e000108","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: An observational study","volume":"3","author":"Smoot","year":"2021","journal-title":"BMJ Neurol. Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1778","DOI":"10.1212\/WNL.0000000000008189","article-title":"Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis","volume":"93","author":"Barkhof","year":"2019","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104523","DOI":"10.1016\/j.msard.2023.104523","article-title":"Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study","volume":"71","author":"Abuaf","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5455\/msm.2022.33.19-24","article-title":"Quality of Life in Multiple Sclerosis Patients: Influence of Gender, Age and Marital Status","volume":"34","author":"Suljic","year":"2022","journal-title":"Mater. Sociomed."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7224\/1537-2073.2018-087","article-title":"Effect of Multiple Sclerosis on Daily Activities, Emotional Well-Being, and Relationships: The Global vsMS Survey","volume":"22","author":"Bass","year":"2020","journal-title":"Int. J. MS Care"},{"key":"ref_15","first-page":"593","article-title":"Quality of life in multiple sclerosis (MS) and role of fatigue, depression, anxiety, and stress: A bicenter study from north of Iran","volume":"19","author":"Salehpoor","year":"2014","journal-title":"Iran. J. Nurs. Midwifery Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","article-title":"No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]","volume":"12","author":"Newsome","year":"2023","journal-title":"Neurol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1177\/1352458518808189","article-title":"Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial","volume":"24","author":"Fox","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40263-024-01074-3","article-title":"Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis","volume":"38","author":"Cortese","year":"2024","journal-title":"CNS Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102724","DOI":"10.1016\/j.msard.2020.102724","article-title":"Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians?","volume":"49","author":"Lynch","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"TW Group (1998). The World Health Organization Quality of Life Assessment (WHOQOL): Development and general psychometric properties. Soc. Sci. Med., 46, 1569\u20131585.","DOI":"10.1016\/S0277-9536(98)00009-4"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.3389\/fpsyg.2019.02934","article-title":"Diagnostic Utility and Psychometric Properties of the Beck Depression Inventory-II Among Korean Adults","volume":"10","author":"Park","year":"2020","journal-title":"Front. Psychol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1017\/S135561772000048X","article-title":"Montreal Cognitive Assessment (MoCA) Performance and Domain-Specific Index Scores in Amnestic Versus Aphasic Dementia","volume":"26","author":"Wood","year":"2020","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"ref_24","first-page":"20552173211007523","article-title":"The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis","volume":"7","author":"Glanz","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hersh, C.M., Pang, M., Miller, D.M., McGinley, M.P., Hyland, M., Ziemssen, T., and Avila, R.L. (2024). Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab. Neurodegener. Dis. Manag.","DOI":"10.2217\/nmt-2023-0047"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e200185","DOI":"10.1212\/CPJ.0000000000200185","article-title":"No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS)","volume":"13","author":"Kister","year":"2023","journal-title":"Neurol. Clin. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/s41598-023-40940-w","article-title":"Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials","volume":"13","author":"Ingwersen","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"592304","DOI":"10.3389\/fneur.2020.592304","article-title":"Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain","volume":"11","author":"Sempere","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/6\/127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:59:31Z","timestamp":1760108371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/6\/127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,16]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["diseases12060127"],"URL":"https:\/\/doi.org\/10.3390\/diseases12060127","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,16]]}}}